Comparable stake leader
OPKO HEALTH, INC.
SEC ownership of Entera Bio Ltd.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001638097.
Disclosed value leader
OPKO HEALTH, INC.
Comparable rows
29/44
Latest evidence
07 May 2026
- Public ticker
- ENTX on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
OPKO HEALTH, INC.
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
29 of 44
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
OPKO HEALTH, INC.
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
07 May 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001638097
- Issuer location
- Jerusalem
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of Entera Bio Ltd. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
OPKO HEALTH, INC.
Disclosed value leader
OPKO HEALTH, INC.
Comparable rows
29/44
Latest evidence
07 May 2026
13D/G
13F
3/4/5
Lead comparable stake: 8.1%
15 rows are not safely comparable across share classes.
13D/G row: OPKO HEALTH, INC.
Showing 1-8 of 44 holder rows.
Quick read
OPKO HEALTH, INC. leads the comparable SEC ownership view at 8.1%.
29 of 44 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens OPKO HEALTH, INC.'s linked filing trail.
Comparable ownership
Top 5
OPKO HEALTH, INC.
8.1%
Point72 Asset Management, L.P.
2.6%
Geno J. Germano
0.09%
Steven D. Rubin
0.03%
Knoll Capital Management, LLC
13%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 44 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| OPKO HEALTH, INC. |
13D/G
|
8.1%
|
$8,660,281
3,685,226 shares
|
$0 | 16 Mar 2025 |
| Point72 Asset Management, L.P. |
13D/G
13F
Company
|
2.6%
|
$2,271,583
1,183,116 shares
|
-$2,915,412 | 30 Sep 2025 |
| Geno J. Germano |
3/4/5
Director
|
0.09%
|
$52,000
40,000 shares
|
+$55,800 | 09 Mar 2026 |
| Steven D. Rubin |
3/4/5
Director
|
0.03%
|
$22,350
15,000 shares
|
+$19,450 | 12 Feb 2026 |
| Knoll Capital Management, LLC |
13F
3/4/5
Company · 10%+ Owner
|
13%
|
$6,470,066
5,881,879 shares
|
— | 31 Mar 2026 |
| RENAISSANCE TECHNOLOGIES LLC |
13F
Company
|
1%
|
$525,521
473,442 shares
|
— | 31 Mar 2026 |
| Parkman Healthcare Partners LLC |
13F
Company
|
0.63%
|
$320,424
288,670 shares
|
— | 31 Mar 2026 |
| CITADEL ADVISORS LLC |
13F
Company
|
0.54%
|
$272,590
245,577 shares
|
— | 31 Mar 2026 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Net insider flow leans to buying over the last 12 months. Net value: +$140,882.
Buys
$140,882
Insiders: 5
Sells
$0
Insiders: 0
Net
+$140,882
Shares: +101,500
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 101,500
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 90,500 | 0 | $120,970 | $0 | +$120,970 |
| 6-9 | 11,000 | 0 | $19,912 | $0 | +$19,912 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-19 of 19 reporting-owner rows connected to Entera Bio Ltd.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
19
Largest Forms 3/4/5 holder
Knoll Capital Management, LLC
Net 12M change
+$140,882
Latest report
07 May 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Knoll Capital Management, LLC | 10%+ Owner | $5,534,275 | Mixed | 14 Nov 2024 | ||
| Gerald M. Lieberman | Director | $823,723 | Mixed | 01 Jan 2026 | ||
| Miranda Jayne Toledano | Chief Executive Officer, Director | $772,186 | +$19,912 | +2.6% | Filing P/S | 29 Dec 2025 |
| Phillip Schwartz | President of R&D, Director | $601,336 | Mixed | 20 Jan 2022 | ||
| Sean Ellis | Director | $231,360 | +$34,620 | +18% | Filing P/S | 05 Mar 2026 |
| Gregory Burshtein | Chief of R&D | $209,826 | Median | 07 May 2026 | ||
| Dana Yaacov-Garbeli | Chief Financial Officer | $190,299 | Median | 07 May 2026 | ||
| Yonatan Malca | Director | $185,024 | Mixed | 01 Jan 2026 | ||
| Hillel Galitzer | Chief Operating Officer | $181,558 | Median | 07 May 2026 | ||
| Gerald M. Ostrov | Director | $180,820 | Mixed | 01 Jan 2026 | ||
| Geno J. Germano | Director | $52,000 | +$55,800 | +107% | Filing P/S | 09 Mar 2026 |
| Steven D. Rubin | Director | $22,350 | +$19,450 | +671% | Filing P/S | 12 Feb 2026 |
| Spiros Jamas | Chief Executive Officer | $9,900 | Mixed | 18 Jan 2022 | ||
| Ramesh Ratan | U.S.based CFO | $9,900 | Mixed | 19 Jan 2022 | ||
| Haya Taitel | Director | +$11,100 | Mixed | 10 Feb 2026 | ||
| Ron Mayron | Director | Mixed | 01 Jan 2024 | |||
| Roger Garceau | Director | Mixed | 01 Jan 2024 | |||
| Leslie Velka Gautam | Chief Business Officer | Mixed | 08 May 2025 | |||
| Arthur C. Santora II | Chief Medical Officer | Mixed | 24 Apr 2023 |
Recent insider transactions for Entera Bio Ltd.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Hillel Galitzer | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 80.6% | 72,993 | 163,566 | 07 May 2026 | Direct | ||
| Dana Yaacov-Garbeli | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 51.6% | 58,394 | 171,441 | 07 May 2026 | By A2Z Counseling Ltd. | ||
| Gregory Burshtein | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 86.4% | 87,591 | 189,033 | 07 May 2026 | Direct | ||
| Geno J. Germano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 100% | $26,000 | $1.30 | 20,000 | 40,000 | 09 Mar 2026 | Direct |
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 5.61% | $12,300 | $1.23 | 10,000 | 188,098 | 05 Mar 2026 | Direct |
| Steven D. Rubin | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 50% | $7,450 | $1.49 | 5,000 | 15,000 | 12 Feb 2026 | Direct |
| Haya Taitel | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $11,100 | $1.48 | 7,500 | $98,479 | 10 Feb 2026 | Direct | |
| Geno J. Germano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $29,800 | $1.49 | 20,000 | $20,000 | 10 Feb 2026 | Direct | |
| Steven D. Rubin | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | $12,000 | $1.20 | 10,000 | 10,000 | 09 Feb 2026 | Direct | |
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 11.2% | $22,320 | $1.24 | 18,000 | 178,098 | 09 Feb 2026 | Direct |
| Haya Taitel | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 40.7% | 26,329 | 90,979 | 01 Jan 2026 | Direct | ||
| Haya Taitel | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Gerald M. Ostrov | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 61.2% | 28,721 | 75,657 | 01 Jan 2026 | Direct | ||
| Gerald M. Ostrov | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Sean Ellis | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 18.8% | 25,371 | 160,098 | 01 Jan 2026 | Direct | ||
| Sean Ellis | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Yonatan Malca | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 63.8% | 30,157 | 77,416 | 01 Jan 2026 | Direct | ||
| Yonatan Malca | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Gerald M. Lieberman | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 12.8% | 38,294 | 338,454 | 01 Jan 2026 | Direct | ||
| Gerald M. Lieberman | ENTX | Stock Option (right to buy) | Award | 33,505 | 33,505 | 01 Jan 2026 | Direct | |||
| Miranda Jayne Toledano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Purchase | 2.65% | $19,912 | $1.81 | 11,000 | 426,575 | 29 Dec 2025 | Direct |
| Miranda Jayne Toledano | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 76.9% | 180,702 | 415,575 | 16 Jul 2025 | Direct | ||
| Miranda Jayne Toledano | ENTX | Stock Option (Right to Buy) | Award | 500,000 | 500,000 | 16 Jul 2025 | Direct | |||
| Gregory Burshtein | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 35% | 26,316 | 101,442 | 16 Jul 2025 | Direct | ||
| Gregory Burshtein | ENTX | Stock Option (right to buy) | Award | 200,000 | 200,000 | 16 Jul 2025 | Direct | |||
| Dana Yaacov-Garbeli | ENTX | Ordinary Shares, par value NIS 0.0000769 per share | Award | 30.3% | 26,316 | 113,047 | 16 Jul 2025 | By A2Z Counseling Ltd. | ||
| Dana Yaacov-Garbeli | ENTX | Stock Option (right to buy) | Award | 130,000 | 130,000 | 16 Jul 2025 | Direct |
* marks a reported price that did not pass the local price check.